RA0429

antibody from Oursmab
Targeting: ITGAL CD11A, LFA-1
Provider product page for RA0429
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0429 - Provider product page
Provider
Oursmab
Product name
Efalizumab (Biosimilar Reference Antibody) (ITGAL)
Antibody type
Monoclonal
Description
Efalizumab (marketed under the brand name Raptiva?) was a humanized monoclonal IgG1 antibody developed as a targeted biologic therapy for moderate to severe chronic plaque psoriasis. It functioned as a T-cell modulator by specifically binding to the CD11a subunit of lymphocyte function-associated antigen-1 (LFA-1). This binding inhibited the interaction between LFA-1 on T cells and intercellular adhesion molecule-1 (ICAM-1) on antigen-presenting cells and vascular endothelium. By blocking this critical costimulatory signal and preventing T-cell adhesion and trafficking into the skin, efalizumab effectively reduced the pathogenic T-cell activation and migration that drive psoriatic plaque formation and inflammation.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
ITGAL protein structure - RA0429 shown in red.